Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne

This study has been completed.
Sponsor:
Information provided by:
Shahid Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT00416585
First received: December 27, 2006
Last updated: January 22, 2008
Last verified: January 2008
  Purpose

serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne


Condition Intervention Phase
Acne
Drug: isotretinoin (Roaccutane)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment

Resource links provided by NLM:


Further study details as provided by Shahid Beheshti Medical University:

Primary Outcome Measures:
  • serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray before the treatment

Secondary Outcome Measures:
  • serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray after the treatment

Estimated Enrollment: 30
Study Start Date: October 2005
Estimated Study Completion Date: November 2006
Detailed Description:

few studies has been done of serum levels Ca, P, PTH and vitamin D metabolites in patients receiving isotretinoin .In this study we measured serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne in 30 patients . the patients had no kown skeletal, endocrine ,renal and gastrointestinal disorders.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • sever acne

Exclusion Criteria:

  • renal disorders
  • gastrointestinal disorders
  • skeletal disorders
  • endocrine disorders
  • drugs such as glucocorticoids , thiazide diuretics, mineral multivitamins, anti acids, tetracyclines
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00416585

Locations
Iran, Islamic Republic of
Shaheed Beheshti Medical University, Skin research center
Tehran, Iran, Islamic Republic of, 198994148
Sponsors and Collaborators
Shahid Beheshti Medical University
Investigators
Study Chair: parviz toossi, md Skin Research Center
Principal Investigator: Hamideh Moravvej, md Skin Research Center
Principal Investigator: Nahid Mohtasham, md Skin Research Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00416585     History of Changes
Other Study ID Numbers: src-hmnm-1385
Study First Received: December 27, 2006
Last Updated: January 22, 2008
Health Authority: Iran: Ministry of Health

Keywords provided by Shahid Beheshti Medical University:
acne
isotretinoin
calcium. vitamin D

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Facial Dermatoses
Sebaceous Gland Diseases
Vitamin D
Ergocalciferols
Vitamins
Isotretinoin
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Bone Density Conservation Agents
Dermatologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 21, 2014